Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade

Get Free Report) shares gapped up before the market opened on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares.

A number of other research firms also recently commented on MTSR. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price on the stock. Evercore ISI began coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Cantor Fitzgerald began coverage on Metsera in a research report on Tuesday, February 25th. They set an “overweight” rating for the company.

Hedge Funds Weigh In On Metsera

Several hedge funds have recently bought and sold shares of the stock. Alphabet Inc. purchased a new stake in shares of Metsera in the first quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Metsera in the first quarter valued at $78,748,000. Wellington Management Group LLP purchased a new stake in shares of Metsera in the first quarter valued at $65,382,000. Alpha Wave Global LP purchased a new stake in shares of Metsera in the first quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Metsera in the first quarter valued at $42,395,000.

Metsera Price Performance

The company’s 50-day simple moving average is $23.40.

Metsera last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.